Presented study is focused on exact immunophenotypic definition of myeloid precursors and their following stages in regenerating bone marrow during treatment of @entity981 / @entity3052 for correct interpretation of the immunophenotype results and proper distinction from @entity41 ( @entity41 ) by multiparameter flow cytometry. This study includes bone marrow samples from 36 controls, 27 @entity1 with @entity3052 , 39 @entity1 with B- @entity981 undergoing therapy who remained in complete remission after treatment and also 30 B- @entity981 @entity1 one year after the end of therapy. We observed substantial expansion of immature bone marrow populations in the regenerating bone marrows, which were identified by expression of @entity2280 and/or @entity2467 markers by 4-color flow cytometry. Myeloid precursors were significantly increased after cessation of induction therapy cycle of B- @entity981 (1.27+/-2.04%, p=0.0064) and also @entity3052 @entity1 (0.87+/-0.77%, p=0.001), but also during follow-up of B- @entity981 @entity1 (1.42+/-2.36%, p=0.0001) when compared with non-treated controls (0.38+/-0.29%). Some cases where their frequencies achieved up to 12% reflect the massive regeneration of myeloid lineage in bone marrow after chemotherapy cycles. Especially in these cases accurate interpretation of such a high frequency of immature myeloid cells as myeloid precursors was very important to exclude incoming @entity1778 . The myeloid precursors represented by @entity2280 + in regenerating bone marrow expressed @entity1195 (94.8+/-5.5%), @entity2467 (38.3+/-26.2%), @entity3053 (91.4+/-5.7%), HLA-DR (90.6+/-7.6%), @entity10793 (73.0+/-20.8%) and @entity1116 (85.2+/-15.6%), while @entity5399 (2.7+/-2.5%), @entity5439 (10.0+/-8.2%) and T or B lymphocyte markers were negative. Comparing immunophenotypes with control bone marrows, only difference in expression of @entity1116 marker was found (85.2+/-15.6% versus 63.0+/-17.4% p=0.024). In addition, according to expression of these markers three different subsets of myeloid precursor cells were identified in regenerating bone marrow samples: @entity2280 + @entity2467 - HLA-DR+, @entity2280 + @entity2467 + HLA-DR+ and @entity2280 - @entity2467 + HLA-DR-/+ without aberrant marker expression. In conclusion for the correct discrimination of @entity41 in @entity3052 it is indispensable to define the range of normality in myeloid differentiation by extensive studies of bone marrows not only from healthy donors but also from regenerating bone marrow of @entity1 undergoing therapy.

Increased myeloid precursors in regenerating bone marrow; implications for detection of XXXX in @entity3052 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity10793 :: ('290', 'Gene') :: ['CD13'] @entity981 :: ('MESH:D054198', 'Disease') :: ['ALL'] @entity41 :: ('MESH:D018365', 'Disease') :: ['MRD', 'minimal residual disease'] @entity5439 :: ('8842', 'Gene') :: ['CD133'] @entity1195 :: ('5788', 'Gene') :: ['CD45'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute leukemia', 'AML'] @entity5399 :: ('7070', 'Gene') :: ['CD90'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['relapse or secondary leukemia'] @entity3053 :: ('952', 'Gene') :: ['CD38'] @entity2467 :: ('3815', 'Gene') :: ['CD117'] @entity2280 :: ('947', 'Gene') :: ['CD34'] @entity1116 :: ('945', 'Gene') :: ['CD33']
@entity41 :: (MESH:D018365,Disease) :: ['minimal residual disease']
